First Tracks Biotherapeutics, Inc.

As of June 30, 2026, First Tracks Biotherapeutics Inc carries a market capitalization of 10.39B, placing it among publicly traded companies globally. Its enterprise value stands at 7.53B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

First Tracks Biotherapeutics Inc's next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, First Tracks Biotherapeutics Inc has 34.56M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, First Tracks Biotherapeutics Inc maintains a current ratio of 14.28, meaning it holds 14.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of June 30, 2026, First Tracks Biotherapeutics Inc holds 2.94B in cash and equivalents against 75.70M in total debt, resulting in a net debt position of -2.94B. Total book value stands at 2.95B, with working capital of 2.89B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026. After subtracting -436,790.00 in capital expenditures, free cash flow totaled -558.10M - equivalent to -16.33 per share.